This article was originally published here
viruses. 2022 May 18;14(5):1089. doi: 10.3390/v14051089.
Coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 is associated with a broad spectrum of diseases ranging from asymptomatic infection to acute respiratory distress syndrome. Some biomarkers can predict disease severity. Among them, the anti-SARS-CoV-2 antibody response has been associated with severe disease. The aim of this study was to assess the correlation between the anti-SARS-CoV-2 serological response and the COVID-19 outcome. Demographic, clinical, and biological data from nasopharyngeal PCR-confirmed COVID-19 hospitalized patients were prospectively collected between April and August 2020 at our facility. All patients were serologically tested weekly for up to three blood samples or until discharge. Two different serological tests were used: a chemiluminescence test and an internally developed Luminex immunoassay. The kinetics of the serological response and the correlation between the antibody titers and outcome were assessed. Of the 70 patients enrolled in the study, 22 required invasive ventilation, 29 required non-invasive ventilation or oxygen supplementation, and 19 did not require oxygen supplementation. The median duration of symptoms at admission for the three groups was 13,8 and 9 days, respectively. Antibody titres gradually increased for up to 3 weeks since symptom onset for patients requiring oxygen supplementation, with significantly higher antibody titres for patients requiring invasive ventilation. Antibody titres at admission were also significantly higher in critically ill patients and serology performed well in predicting the need for invasive ventilation (AUC: 0.79, 95% CI: 0.67-0.9). Serology at admission can be a good indicator to identify severe COVID-19 patients who require invasive mechanical ventilation.
PMID:35632830 | DOI: 10.3390/v14051089